Cargando…

Statin therapy for preventing cardiovascular diseases in patients treated with tacrolimus after kidney transplantation

BACKGROUND: Lipid abnormalities are prevalent in tacrolimus-treated patients. The aim of the study was to evaluate the preventive effects of statin therapy on major adverse cardiovascular events (MACE) in patients treated with tacrolimus-based immunosuppression after kidney transplantation (KT), and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Han, Nayoung, Han, Seung Hee, Song, Yun-Kyoung, Kim, Myeong Gyu, Kim, Yon Su, Kim, In-Wha, Oh, Jung Mi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5701562/ https://www.ncbi.nlm.nih.gov/pubmed/29200861 http://dx.doi.org/10.2147/TCRM.S147327

Ejemplares similares

Model based development of tacrolimus dosing algorithm considering CYP3A5 genotypes and mycophenolate mofetil drug interaction in stable kidney transplant recipients
por: Kim, Jae Hyun, et al.
Publicado: (2019)

Whole exome sequencing for the identification of CYP3A7 variants associated with tacrolimus concentrations in kidney transplant patients
por: Sohn, Minji, et al.
Publicado: (2018)

Author Correction: Whole exome sequencing for the identification of CYP3A7 variants associated with tacrolimus concentrations in kidney transplant patients
por: Sohn, Minji, et al.
Publicado: (2020)

Increased Exposure of Tacrolimus by Co-administered Mycophenolate Mofetil: Population Pharmacokinetic Analysis in Healthy Volunteers
por: Kim, Jae Hyun, et al.
Publicado: (2018)

Pharmacokinetics of tacrolimus according to body composition in recipients of kidney transplants
por: Han, Seung Seok, et al.
Publicado: (2012)

Monitoring the Intracellular Tacrolimus Concentration in Kidney Transplant Recipients with Stable Graft Function
por: Han, Seung Seok, et al.
Publicado: (2016)

Discovery of Biomarkers Related to Interstitial Fibrosis and Tubular Atrophy among Kidney Transplant Recipients by mRNA-Sequencing
por: Lee, Hyun Kyung, et al.
Publicado: (2023)

Effect of additive calcium administration on FGF23 levels in patients with mild chronic kidney disease treated with calcitriol: a randomized, open-labeled clinical trial
por: Han, Nayoung, et al.
Publicado: (2017)

CYP3A5 genotype-based model to predict tacrolimus dosage in the early postoperative period after living donor liver transplantation
por: Ji, Eunhee, et al.
Publicado: (2018)

Genetic polymorphisms of CASR and cancer risk: evidence from meta-analysis and HuGE review
por: Jeong, Sohyun, et al.
Publicado: (2016)

Impact of depression on change in coronary heart disease risk status: the Korean Genome and Epidemiology Study (KoGES)
por: Jang, Ha Young, et al.
Publicado: (2018)

Tacrolimus trough levels in kidney transplant recipients
por: Hwang, Young Hui, et al.
Publicado: (2021)

Analysis of Issues and Future Trends Impacting Drug Safety in South Korea
por: Kim, Myeong Gyu, et al.
Publicado: (2019)

Comparison of Transplant Outcomes for Low-level and Standard-level Tacrolimus at Different Time Points after Kidney Transplantation
por: Jung, Hee-Yeon, et al.
Publicado: (2019)

Association of high intra-patient variability in tacrolimus exposure with calcineurin inhibitor nephrotoxicity in kidney transplantation
por: Kim, Hyokee, et al.
Publicado: (2023)

Association of Intrapatient Variability of Tacrolimus Concentration With Early Deterioration of Chronic Histologic Lesions in Kidney Transplantation
por: Mo, Hyejin, et al.
Publicado: (2019)

A case of tacrolimus-induced encephalopathy after kidney transplantation
por: Kim, Myoung Uk, et al.
Publicado: (2011)

Trends in the effects of pre‐transplant diabetes on mortality and cardiovascular events after kidney transplantation
por: Jeon, Ja Young, et al.
Publicado: (2020)

Association between medication adherence and intrapatient variability in tacrolimus concentration among stable kidney transplant recipients
por: Ko, Hyunmin, et al.
Publicado: (2021)

Assessment of adverse events related to anti-influenza neuraminidase inhibitors using the FDA adverse event reporting system and online patient reviews
por: Han, Nayoung, et al.
Publicado: (2020)

Combination of Genome-Wide Polymorphisms and Copy Number Variations of Pharmacogenes in Koreans
por: Han, Nayoung, et al.
Publicado: (2021)

Adverse Events Related to Off-Label Drugs Using Spontaneous Adverse Event Reporting Systems
por: Han, Nayoung, et al.
Publicado: (2021)

Severe anorexia and weight loss induced by tacrolimus in kidney transplant recipients
por: Hwang, Hong Pil, et al.
Publicado: (2021)

Flat Pattern Peaks of Tacrolimus Absorption and Associated Pharmacogenomic Variants in Kidney Transplantation Recipients
por: Kim, Suh Min, et al.
Publicado: (2022)

Comparison of the long-term efficacy and safety of generic Tacrobell with original tacrolimus (Prograf) in kidney transplant recipients
por: Son, Seung Yeon, et al.
Publicado: (2017)

Tacrolimus Formulation, Exposure Variability, and Outcomes in Kidney Transplant Recipients
por: Lai, Elaine F., et al.
Publicado: (2022)

Evaluation of Nutrient Intake in Early Post Kidney Transplant Recipients
por: Rho, Mi Ra, et al.
Publicado: (2013)

Impact of Post-Transplant Diabetes Mellitus on Survival and Cardiovascular Events in Kidney Transplant Recipients
por: Jeon, Ja Young, et al.
Publicado: (2023)

Maculopathy Associated with Tacrolimus (FK 506)
por: Koh, Taehyuk, et al.
Publicado: (2011)

Epidermal Cysts in a Tacrolimus Treated Renal Transplant Recipient
por: Ahn, In Su, et al.
Publicado: (2011)

The Pharmacogenetics of Tacrolimus in Corticosteroid-Sparse Pediatric and Adult Kidney Transplant Recipients
por: Madsen, Mads Juul, et al.
Publicado: (2017)

Impact of Pneumocystis jirovecii pneumonia on kidney transplant outcome
por: Kim, Ji Eun, et al.
Publicado: (2019)

Clinical significance of tacrolimus intra-patient variability on kidney transplant outcomes according to pre-transplant immunological risk
por: Kim, Eun Jin, et al.
Publicado: (2021)

Tacrolimus trough levels higher than 6 ng/mL might not be required after a year in stable kidney transplant recipients
por: Jung, Hee-Yeon, et al.
Publicado: (2020)

Gut Microbiota and Tacrolimus Dosing in Kidney Transplantation
por: Lee, John R., et al.
Publicado: (2015)

Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of Tacrolimus in Kidney Transplantation
por: Yu, Meng, et al.
Publicado: (2018)

HMG-CoA reductase inhibitors in kidney transplant recipients receiving tacrolimus: statins not associated with improved patient or graft survival
por: Younas, Nizar, et al.
Publicado: (2010)

Early statin use in ischemic stroke patients treated with recanalization therapy: retrospective observational study
por: Kang, Jihoon, et al.
Publicado: (2015)

Tuberculum sellae meningioma with possible tacrolimus neurotoxicity manifesting as manic-like psychosis after kidney transplantation
por: Seo, Eun Hyun, et al.
Publicado: (2019)

Efficacy and safety of a switch from twice-daily tacrolimus to once-daily generic tacrolimus in stable liver transplant patients
por: Kim, Jong Man, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_nogqa328b3cgflco7671vb64js